Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,617
  • Shares Outstanding, K 11,798
  • Annual Sales, $ 9,760 K
  • Annual Income, $ -41,300 K
  • EBIT $ -30 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.87
  • Price/Sales 1.18
  • Price/Cash Flow N/A
  • Price/Book 0.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9000 +15.56%
on 11/11/24
1.2000 -13.33%
on 11/13/24
-0.1300 (-11.11%)
since 10/22/24
3-Month
0.9000 +15.56%
on 11/11/24
1.4100 -26.24%
on 09/30/24
-0.1900 (-15.45%)
since 08/22/24
52-Week
0.9000 +15.56%
on 11/11/24
24.3000 -95.72%
on 12/04/23
-19.5340 (-94.95%)
since 11/22/23

Most Recent Stories

More News
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to...

JAGX : 1.0400 (+5.62%)
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to...

JAGX : 1.0400 (+5.62%)
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases

JAGX : 1.0400 (+5.62%)
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases

JAGX : 1.0400 (+5.62%)
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.

SRNE : 0.0026 (-13.33%)
TNXP : 0.1900 (-6.95%)
IBB : 137.97 (+1.37%)
JAGX : 1.0400 (+5.62%)
NVAX : 8.48 (+5.47%)
INO : 4.11 (+1.23%)
GILD : 90.14 (+0.42%)
MRNA : 40.63 (+6.22%)
VXRT : 0.6049 (+0.93%)
IBIO : 2.61 (+6.53%)
XBI : 96.17 (+1.98%)
PFE : 25.58 (+1.79%)
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Each October, breast cancer awareness gains momentum through impactful campaigns and advancements in...

ONCY : 0.9472 (-3.35%)
PCSA : 0.8625 (-1.99%)
JAGX : 1.0400 (+5.62%)
BCTX : 0.7217 (-8.53%)
ONC.TO : 1.34 (-2.19%)
RHHBY : 35.4650 (+0.50%)
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

FDA-approved Gelclair® is company's third commercialized prescription product

JAGX : 1.0400 (+5.62%)
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

FDA-approved Gelclair® is company's third commercialized prescription product

JAGX : 1.0400 (+5.62%)
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued for core rare disease target indication for crofelemer

JAGX : 1.0400 (+5.62%)
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued for core rare disease target indication for crofelemer

JAGX : 1.0400 (+5.62%)

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

3rd Resistance Point 1.0420
2nd Resistance Point 1.0206
1st Resistance Point 1.0027
Last Price 1.0400
1st Support Level 0.9634
2nd Support Level 0.9420
3rd Support Level 0.9241

See More

52-Week High 24.3000
Fibonacci 61.8% 15.3612
Fibonacci 50% 12.6000
Fibonacci 38.2% 9.8388
Last Price 1.0400
52-Week Low 0.9000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar